BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

Immix Biopharma (IMMX)Immix BiopharmaCompany update

- 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) -

- To-date, all patients achieving MRD-negativity reached CR within one year of treatment -

- Across all forty-five patients,...

Related news

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

KURAKura Oncology2026-09-29 09:15 EST

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

REGNRegeneron Pharmaceuticals2026-10-01 15:35 EST

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-10-05 13:45 EST

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Stock data

Close
10.23 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States